Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Verify all details directly with Hers and your healthcare provider before making decisions
Coming soon to Pharmulous Pharmulous is preparing to support eligible patients with oral GLP-1 weight management options once they become available, clinically appropriate and supported by UK guidance
PubMed laboratory research record [PMID: 41370811] PubMed record related to this compound for laboratory literature review
Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy [18] Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) [19] [20] Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention
We need more data
Will I still struggle with hunger while taking GLP-1 medications
